Floatz logo

Durvalumab

Nonpapillary Renal Cell Carcinoma

Explore 112 assets in Nonpapillary Renal Cell Carcinoma →
Floatz Rating
B62/100
Confidence
Indicative
v0.2
Sponsor
AstraZeneca
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT04504669CT.gov
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
—Completed———
NCT03682289CT.gov
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
—Active Not Recruiting———
NCT03308396CT.gov
Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
—Active Not Recruiting———
NCT02626130CT.gov
Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer
—Completed———
NCT02118337CT.gov
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Nonpapillary Renal Cell Carcinoma

AssetSponsorPhaseRating
Durvalumab (this asset)AstraZenecaP2B · 62
GirentuximabMassachusetts General HospitalP3BB
Clostridium Butyricum Miyairi 588City of Hope Medical CenterP3BB
PazopanibAcademic and Community Cancer Research UnitedP4BB
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, DimerRegeneron PharmaceuticalsP2BB
NivolumabFred Hutchinson Cancer CenterP3BB
CabozantinibSWOG Cancer Research NetworkP3BB
CyclophosphamideCity of Hope Medical CenterP3B
IrinotecanM.D. Anderson Cancer CenterP3B

+42 more in the Nonpapillary Renal Cell Carcinoma cohort

Other indications for Durvalumab

IndicationSponsorPhaseRating
Ovarian Carcinoma—P2BB · 70
Primary Peritoneal Carcinoma—P2BB · 70
Urothelial Carcinoma—P3BB · 70

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Durvalumab in Nonpapillary Renal Cell Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/durvalumab-nonpapillary-renal-cell-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →